Use of calcium antagonists in renal patients: Therapeutic benefit or medical malpractice?

Current Hypertension Reports

Volumn 5, Issue 5, 2003, Pages 430-436

  Nigbor, Douglas A ^a   Lewis, Julia B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CHLOROTHIAZIDE; CILAZAPRIL; CYCLOSPORIN; DILTIAZEM; DOXAZOSIN; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; ISRADIPINE; LISINOPRIL; METOPROLOL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PERINDOPRIL; RAMIPRIL; TACROLIMUS; TRANDOLAPRIL; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; DIABETIC NEPHROPATHY; DRUG EFFECT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MALPRACTICE;

CALCIUM CHANNEL BLOCKERS; DIABETIC NEPHROPATHIES; DIHYDROPYRIDINES; HUMANS; HYPERTENSION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALPRACTICE; RENIN-ANGIOTENSIN SYSTEM;

EID: 0642343036     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0090-1     Document Type: Review

References (52)

1. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997, 157:2413-2446.
2. Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 2000, 36:646-661.
3. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
4. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
5. Parving HH, Lehnert H, Bröchner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
6. Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (the JNC 7 report). JAMA 2003, 289:2560-2572.
7. Levin S: Top 200 Prescriptions for 2001 by Number of US Prescriptions Dispensed. http://www.pharmclips.com/top200_rank.shtml. Accessed July, 2003.
8. IMS Health: Leading Products by Global Pharmaceutical Sales, 2002. http://www.imshealth.com/ims/portal/front/articleC/ 0,2777,6599_41527077_41551508,00.html. Accessed July, 2003.
9. 2 Rx Market: A Look in the Rearview Mirror. http://www.drugtopics.com. Accessed July, 2003.
10. Mann JF, Gerstein HC, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Int Med 2001, 134:629-636.
11. Demarie BK, Bakris GL: Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Int Med 1990, 113:987-988.
12. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al.: Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995, 10:1963-1974.
13. Tarif N, Bakris GL: Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997, 12:2244-2250.
14. Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997, 350:757-764.
15. Voyaki SM, Staessen JA, Thijs L, et al.: Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001, 19:511-519.
16. National Intervention Cooperative Study in Elderly Hypertensives Study Group: Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999, 34:1129-1133.
17. Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366-372.
18. Tatti P, Pahor M, Byington R, et al.: Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597-603.
19. The ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 238:1967-1975.
20. The ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002, 288:2981-2997.
21. Janssen JJ, Gans RO, van der Meulen J, et al.: Comparison between the effects of amlodipine and lisinopril on proteinuria in nondiabetic renal failure. Am J Hypertens 1998, 11:1074-1079.
22. Holdaas H, Hartmann A, Berg KJ, et al.: Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant 1998, 13:3096-3102.
23. Kumagai H, Hayashi K, Kumamaru H, et al.: Amlodipine is comparable to angintensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. Am J Hypertens 2000, 13:980-985.
24. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863.
25. Ruggenenti P, Perna A, Benini R, et al.: Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol 1998, 9:2096-2101.
26. Maccariello ER, Genelhu de Abreu Fagundes V, Francischetti EA: The effects of isradipine and spirapril as monotherapy and combined therapy on blood pressure, renal hemodynamics, natriuresis, and urinary kallikrein in hypertensive nephropathy. Am J Hypertens 1997, 10:541-545.
27. Hemmelder MH, de Zeeuw D, de Jong PE: Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. Nephrol Dial Transplant 1999, 14:98-104.
28. Herlitz H, Harris K, RislerT, et al.: The effects of ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros study. Nephrol Dial Transplant 2001, 16:2158-2165.
29. The PROCOPA Study Group: Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. J Hypertens 2002, 20:729-737.
30. Boero R, Rollino C, Massara C, et al.: Verapamil versus amlodipine in proteinuric nondiabetic nephropathies treated with trandolapril (WANNTT) study. Am J Kidney Dis 2003, 42:67-74.
31. Bakris GL, Weir MR, DeQuattro V, et al.: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998, 54:1283-1289.
32. Wright JT, Bakris G, Greene T, et al., for the AASK study group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 2002, 288:2421-2431.
33. Agodoa LY, Appel L, Bakris GL, et al., for the AASK study group: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA 2001, 285:2719-2728.
34. Bakris GL, Copley JB, Vicknair N, et al.: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996, 50:1641-1650.
35. Bakris GL, Mangrum A, Copley JB, et al.: Effect of calcium channel or b-blockade on the progression of diabetic nephropathy in African-Americans. Hypertension 1997, 29:744-750.
36. Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645-652.
37. Estacio RO, Schrier RW: Antihypertensive therapy in type 2 diabetes: Implications of the Appropriate Blood pressure Control in Diabetes (ABCD) trial. Am J Cardiol 1998, 82:9R-14R.
38. Estacio RO, Jeffers BW, Gifford N, et al.: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23:B54-B64.
39. Schrier RW, Estacio RO, Esler E, et al.: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy, and strokes. Kidney Int 2002, 61:1086-1097.
40. Baba S, for the J-MIND Study Group: Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001, 54:191-201.
41. Velussi M, Brocco E, Frigato F, et al.: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996, 45:216-222.
42. Romero R, Salinas I, Lucas A, et al.: Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. Diabetes Res Clin Pract 1992, 17:191-198.
43. Gausch A, Parham M, Zayas C, et al.: Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. J Am Soc Nephrol 1997, 8:793-798.
44. Fogari R, Zoppi A, Corradi L, et al.: Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1998, 13:47-53.
45. Jerums G, Allen TJ, Campbell DJ et al.: Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001, 37:890-899.
46. Crepaldi G, Carta Q, Defarrari G, et al.: Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998, 21:104-110.
47. English J, Evan A, Houghton DC, et al.: Cyclosporine-induced acute renal dysfunction in the rat. Transplantation 1987, 44:135-141.
48. Raman GV, Feehally J, Coates RA, et al.: Renal effects of amlodipine in normotensive renal transplant recipients. Nephrol Dial Transplant 1999, 14:384-388.
49. van Riemsdijk IC, Mulder PG, de Fijter JW, et al.: Addition of isradipine results in a better renal function after kidney transplantation: A double-blind, randomized, placebo-controlled, multicenter study. Ransplantation 2000, 70:122-126.
50. Rahn KH, Barenbrock M, Fritschka E, et al.: Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999, 354:1415-1420.
51. Midtvedt K, Hartmann A, Foss A, et al.: Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001, 72:1787-1792.
52. Curtis JJ: Hypertensinogenic mechanism of the calcineurin inhibitors. Curr Hypertens Rep 2002, 4:377-380.